Global X Genomics & Biotechnology ETF (NASDAQ:GNOM – Get Rating) was the recipient of a large increase in short interest during the month of January. As of January 15th, there was short interest totalling 130,200 shares, an increase of 45.0% from the December 31st total of 89,800 shares. Based on an average daily volume of 101,000 shares, the short-interest ratio is presently 1.3 days.
Institutional Inflows and Outflows
→ The Next Big Crisis Is Here (From Porter & Company)
Institutional investors have recently made changes to their positions in the business. HighTower Advisors LLC raised its holdings in Global X Genomics & Biotechnology ETF by 3.6% in the 1st quarter. HighTower Advisors LLC now owns 62,395 shares of the company’s stock worth $939,000 after purchasing an additional 2,140 shares during the period. Royal Bank of Canada raised its holdings in Global X Genomics & Biotechnology ETF by 38.7% in the 1st quarter. Royal Bank of Canada now owns 18,955 shares of the company’s stock valued at $285,000 after buying an additional 5,291 shares during the period. Jane Street Group LLC purchased a new position in Global X Genomics & Biotechnology ETF during the first quarter worth about $576,000. Stratos Wealth Partners LTD. increased its position in shares of Global X Genomics & Biotechnology ETF by 55.1% during the second quarter. Stratos Wealth Partners LTD. now owns 22,070 shares of the company’s stock valued at $270,000 after acquiring an additional 7,845 shares during the last quarter. Finally, Portland Global Advisors LLC purchased a new stake in Global X Genomics & Biotechnology ETF during the second quarter worth about $2,433,000.
Global X Genomics & Biotechnology ETF Stock Up 0.9 %
NASDAQ:GNOM traded up $0.12 during trading hours on Friday, hitting $13.83. 64,314 shares of the company were exchanged, compared to its average volume of 69,001. The company’s 50 day moving average price is $13.07 and its 200-day moving average price is $13.45. Global X Genomics & Biotechnology ETF has a 52-week low of $10.48 and a 52-week high of $17.02.
Global X Genomics & Biotechnology ETF Company Profile
Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Global X Genomics & Biotechnology ETF, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Global X Genomics & Biotechnology ETF wasn’t on the list.
While Global X Genomics & Biotechnology ETF currently has a “hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
